Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06978829 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This prospective, single-arm, Phase II study aims to evaluate the efficacy, safety, and surgical conversion rate of Cetuximab combined with Tislelizumab and chemotherapy for unresectable LA HNSCC.
Trial Details
NCT Number NCT06978829
Lead Sponsor Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Conditions
(from sponsor)		 LA HNSCC
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov